Wells Fargo lowered the firm’s price target on Bio-Rad (BIO) to $345 from $360 and keeps an Equal Weight rating on the shares. The firm says ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback